Abbott Laboratories
Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
Our approach to innovation builds on strong science combined with the drive to find solutions where the need is the greatest. Our science. If we bring a new medicine to market, it can help patients worldwide, as opposed to the 20 or so patients we might see in clinic in one day.
AbbVie In Singapore. People. Passion. Possibilities. ®. At AbbVie, we combine advanced science, expertise and passion to solve. serious health issues and have a remarkable impact on people’s lives. We are. committed to improving health care in markets where we operate. Passionate about our work.
It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. [2] The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection.
Finding Better Solutions to the Toughest Challenges. Research and innovation are the cornerstones of our business. We focus on discovering, developing and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This includes Immunology, Oncology, Neuroscience and Virology.
Jan 25, 2024 · This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network. Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide.
Focused on results, dedicated to innovations. AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.
6 days ago · Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD); NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients ...
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
